Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of lifeBente Braun, Vivien Häußler, Christoph Heesen et al.|Multiple Sclerosis and Related Disorders|2023Cited by 5